ATS 2026: Insmed Shines in Bronchiectasis with Spotlight on Brinsupri

Why It Matters

Brinsupri offers the first non‑antibiotic, anti‑inflammatory therapy for bronchiectasis, positioning Insmed to reshape treatment standards and capture a high‑growth market.

Key Takeaways

• Phase III ASPEN post‑hoc shows dose‑dependent symptom improvement versus placebo
• Survey of 1,050 patients reveals 77% experience health decline after exacerbations
• Q1 2026 Brinsupri sales hit $207.9 M, supporting $1 B full‑year target
• European launch postponed over MFN pricing uncertainty, despite strong clinical data
• Insmed’s “Suspect BE” program aims to improve early bronchiectasis diagnosis

Pulse Analysis

Bronchiectasis, a chronic lung disease characterized by persistent airway inflammation, has long lacked targeted, non‑antibiotic treatments. Brinsupri (brensocatib) fills this gap as the first dipeptidyl peptidase‑1 inhibitor, directly modulating neutrophilic activity that drives tissue damage. By shifting the therapeutic paradigm away from off‑label antibiotics, the drug promises to reduce antibiotic resistance pressures while improving patients’ quality of life—a compelling value proposition for clinicians and payers alike.

At the ATS 2026 conference, Insmed leveraged a multi‑pronged strategy to cement Brinsupri’s clinical credibility. A poster dissecting post‑hoc analyses of the Phase III ASPEN trial showed that both 10 mg and 25 mg doses produced numerical gains in the QOL‑B RSS score over 52 weeks, with the higher dose delivering the most pronounced benefit in severe exacerbation subgroups. Complementary survey data from over a thousand patients underscored the profound emotional and functional toll of exacerbations, reinforcing regulatory focus on patient‑reported outcomes. The company’s “Suspect BE” educational push and on‑site interactive booths further amplified disease awareness, laying groundwork for broader adoption.

Commercially, Brinsupri is already delivering momentum. Q1 2026 net sales reached $207.9 million, keeping Insmed on track for its $1 billion annual revenue target. Yet the European rollout stalls as the firm awaits guidance on the U.S. Most Favored Nation pricing framework, a delay that could cede early market share to potential competitors. Assuming resolution, Brinsupri’s robust efficacy data, coupled with its pioneering mechanism, positions it to become the de‑facto standard of care for non‑cystic fibrosis bronchiectasis worldwide.